NeurologyLive Friday 5 — January 24, 2020
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 24, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Podcast: Why EMS Transport Protocols Matter in Stroke
Episode 6, "Time Is Brain: Why EMS Transport Protocols Matter" features an interview with Donald Frei, MD, a neurointerventional surgeon at Swedish Medical Center and Radiology Imaging Associates in Denver, Colorado, and past president of the Society for Neurointerventional Surgery.
2: Humble Pie: The Art of Eating Your Words in Medicine
Danielle B. Cross, MD, MS, a neurology resident in training, shares her thoughts on the importance of humility in medicine—an "acquired taste as mandatory a part of the diet of any well-meaning clinician as vegetables."
3: Risdiplam Meets Primary End Point in SMA Type 1
Part 2 of the pivotal FIREFISH clinical trial met its primary end point in infants aged 1 to 7 months with Type 1 spinal muscular atrophy, with statistically significant and medically meaningful motor milestone improvements.
4: Suvorexant Increases Sleep Time in Patients With Alzheimer Dementia, Insomnia
The drug proved effective in extending total sleep time over a 4-week study period, with minimal adverse events observed.
5: FDA Gives Green Light to Healey ALS Platform Trial
The first trial of its kind in amyotrophic lateral sclerosis will first examine 3 drugs and add additional treatments as more become available.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Perispinal Etanercept Shows No Efficacy in Treating Chronic Stroke
September 16th 2025
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025